Black Diamond Therapeutics (BDTX) Income towards Parent Company: 2018-2021
Historic Income towards Parent Company for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$25.5 million.
- Black Diamond Therapeutics' Income towards Parent Company fell 16.25% to -$25.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$111.6 million, marking a year-over-year decrease of 68.00%. This contributed to the annual value of -$123.4 million for FY2021, which is 88.32% down from last year.
- According to the latest figures from Q4 2021, Black Diamond Therapeutics' Income towards Parent Company is -$25.5 million, which was up 26.30% from -$34.6 million recorded in Q3 2021.
- Black Diamond Therapeutics' Income towards Parent Company's 5-year high stood at -$3.0 million during Q4 2018, with a 5-year trough of -$34.6 million in Q3 2021.
- Moreover, its 3-year median value for Income towards Parent Company was -$14.3 million (2020), whereas its average is -$16.8 million.
- Data for Black Diamond Therapeutics' Income towards Parent Company shows a maximum YoY crashed of 235.30% (in 2020) over the last 5 years.
- Quarterly analysis of 4 years shows Black Diamond Therapeutics' Income towards Parent Company stood at -$3.0 million in 2018, then crashed by 225.15% to -$9.9 million in 2019, then tumbled by 121.42% to -$21.9 million in 2020, then decreased by 16.25% to -$25.5 million in 2021.
- Its Income towards Parent Company was -$25.5 million in Q4 2021, compared to -$34.6 million in Q3 2021 and -$29.6 million in Q2 2021.